Free Trial

Insmed (INSM) Competitors

Insmed logo
$96.14 -0.81 (-0.84%)
Closing price 07/8/2025 04:00 PM Eastern
Extended Trading
$97.28 +1.14 (+1.19%)
As of 06:15 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

INSM vs. REGN, ALNY, ARGX, BNTX, RPRX, BIIB, ILMN, GMAB, INCY, and EXEL

Should you be buying Insmed stock or one of its competitors? The main competitors of Insmed include Regeneron Pharmaceuticals (REGN), Alnylam Pharmaceuticals (ALNY), argenex (ARGX), BioNTech (BNTX), Royalty Pharma (RPRX), Biogen (BIIB), Illumina (ILMN), Genmab A/S (GMAB), Incyte (INCY), and Exelixis (EXEL). These companies are all part of the "med - biomed/gene" industry.

Insmed vs. Its Competitors

Regeneron Pharmaceuticals (NASDAQ:REGN) and Insmed (NASDAQ:INSM) are both large-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their earnings, risk, profitability, dividends, valuation, media sentiment, analyst recommendations and institutional ownership.

83.3% of Regeneron Pharmaceuticals shares are owned by institutional investors. 7.0% of Regeneron Pharmaceuticals shares are owned by company insiders. Comparatively, 3.0% of Insmed shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Regeneron Pharmaceuticals has a net margin of 31.94% compared to Insmed's net margin of -265.93%. Regeneron Pharmaceuticals' return on equity of 15.27% beat Insmed's return on equity.

Company Net Margins Return on Equity Return on Assets
Regeneron Pharmaceuticals31.94% 15.27% 11.93%
Insmed -265.93%-446.98%-52.70%

Regeneron Pharmaceuticals currently has a consensus target price of $813.57, suggesting a potential upside of 48.53%. Insmed has a consensus target price of $108.07, suggesting a potential upside of 12.41%. Given Regeneron Pharmaceuticals' higher possible upside, equities research analysts plainly believe Regeneron Pharmaceuticals is more favorable than Insmed.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Regeneron Pharmaceuticals
1 Sell rating(s)
6 Hold rating(s)
15 Buy rating(s)
3 Strong Buy rating(s)
2.80
Insmed
0 Sell rating(s)
0 Hold rating(s)
17 Buy rating(s)
0 Strong Buy rating(s)
3.00

In the previous week, Regeneron Pharmaceuticals had 27 more articles in the media than Insmed. MarketBeat recorded 35 mentions for Regeneron Pharmaceuticals and 8 mentions for Insmed. Insmed's average media sentiment score of 1.13 beat Regeneron Pharmaceuticals' score of 0.95 indicating that Insmed is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Regeneron Pharmaceuticals
19 Very Positive mention(s)
3 Positive mention(s)
8 Neutral mention(s)
2 Negative mention(s)
1 Very Negative mention(s)
Positive
Insmed
5 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Regeneron Pharmaceuticals has a beta of 0.33, indicating that its stock price is 67% less volatile than the S&P 500. Comparatively, Insmed has a beta of 0.9, indicating that its stock price is 10% less volatile than the S&P 500.

Regeneron Pharmaceuticals has higher revenue and earnings than Insmed. Insmed is trading at a lower price-to-earnings ratio than Regeneron Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Regeneron Pharmaceuticals$14.20B4.16$4.41B$39.2813.94
Insmed$363.71M50.15-$913.77M-$5.95-16.16

Summary

Regeneron Pharmaceuticals beats Insmed on 12 of the 17 factors compared between the two stocks.

Get Insmed News Delivered to You Automatically

Sign up to receive the latest news and ratings for INSM and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding INSM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

INSM vs. The Competition

MetricInsmedMED IndustryMedical SectorNASDAQ Exchange
Market Cap$18.39B$2.87B$5.47B$8.95B
Dividend YieldN/A2.46%5.25%4.04%
P/E Ratio-16.1620.8027.0020.11
Price / Sales50.15286.27429.45119.84
Price / CashN/A41.1936.8257.86
Price / Book60.097.487.985.56
Net Income-$913.77M-$55.04M$3.16B$248.40M
7 Day Performance-2.14%2.44%2.38%4.67%
1 Month Performance36.02%1.90%2.17%6.64%
1 Year Performance36.82%4.35%33.80%21.31%

Insmed Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
INSM
Insmed
4.5531 of 5 stars
$96.14
-0.8%
$108.07
+12.4%
+37.2%$18.39B$363.71M-16.161,271Positive News
Analyst Forecast
REGN
Regeneron Pharmaceuticals
4.9355 of 5 stars
$525.00
+0.8%
$813.57
+55.0%
-47.9%$56.68B$14.20B13.3711,900Analyst Revision
ALNY
Alnylam Pharmaceuticals
4.1176 of 5 stars
$326.09
+1.0%
$340.00
+4.3%
+24.5%$42.52B$2.35B-156.022,000Positive News
Analyst Forecast
ARGX
argenex
4.3888 of 5 stars
$551.22
-1.6%
$729.93
+32.4%
+23.4%$33.66B$2.58B34.00650Analyst Upgrade
High Trading Volume
BNTX
BioNTech
1.4391 of 5 stars
$106.47
-0.2%
$137.86
+29.5%
+38.7%$25.59B$2.98B-31.313,080
RPRX
Royalty Pharma
4.8864 of 5 stars
$36.03
+0.4%
$47.33
+31.4%
+38.1%$20.26B$2.26B19.4880Positive News
BIIB
Biogen
4.9571 of 5 stars
$125.59
-0.4%
$188.48
+50.1%
-41.0%$18.40B$9.68B12.407,605
ILMN
Illumina
4.8726 of 5 stars
$95.41
+0.7%
$127.39
+33.5%
-7.9%$15.10B$4.37B-15.729,030Positive News
Analyst Forecast
GMAB
Genmab A/S
4.0088 of 5 stars
$20.66
+0.8%
$37.60
+82.0%
-16.6%$13.25B$3.12B11.742,682Analyst Forecast
INCY
Incyte
4.7635 of 5 stars
$68.10
-0.4%
$74.53
+9.4%
+16.3%$13.18B$4.24B212.822,617Trending News
Insider Trade
EXEL
Exelixis
4.7059 of 5 stars
$44.08
+0.9%
$43.56
-1.2%
+97.0%$12.02B$2.17B20.041,147Trending News
Analyst Forecast
Options Volume

Related Companies and Tools


This page (NASDAQ:INSM) was last updated on 7/9/2025 by MarketBeat.com Staff
From Our Partners